ROC1 Antibody

What is ROC1 and what is its function in cellular processes?

ROC1/RBX1 functions as an essential catalytic subunit of cullin-RING E3 ubiquitin ligases, facilitating the transfer of ubiquitin to target proteins for subsequent proteasomal degradation. This process regulates numerous cellular functions including cell cycle progression, signal transduction, and DNA repair. ROC1 disruption in mouse models causes early embryonic lethality at E7.5 due to proliferation failure resulting from p27 accumulation . The protein's fundamental role in cellular homeostasis makes it a significant subject for cancer research and therapeutic targeting.

How is ROC1 expression altered in cancer tissues compared to normal tissues?

ROC1 is significantly overexpressed in primary human tumor tissues compared to adjacent normal tissues. Immunohistochemistry studies have demonstrated that ROC1 is expressed weakly in normal lung, liver, and breast tissues, but is strongly overexpressed in corresponding carcinomas . In a detailed analysis of lung cancer tissues, approximately 77% of normal tissue samples showed very weak ROC1 staining (group 1), while only 5% of adenocarcinoma samples fell into this category . More strikingly, approximately 95% of squamous carcinomas showed moderate to strong ROC1 staining (groups 3-5) . Similar overexpression patterns have been observed across multiple cancer types, suggesting ROC1's potentially essential role in tumor cell proliferation and survival.

What antibody dilutions are optimal for ROC1 detection in different experimental applications?

For optimal ROC1 detection across various applications:

These dilutions should be optimized for each specific experimental setup and antibody lot. For tissue microarray (TMA) construction and IHC analysis, ROC1 expression levels can be analyzed semi-quantitatively using an immunoreactivity-scoring system as described in previous studies .

How should ROC1 silencing experiments be designed to study its function in cancer progression?

ROC1 silencing experiments should incorporate the following components:

• siRNA Selection: Two validated siRNA sequences have demonstrated efficacy:

  • siROC1-1: 5'-GACTTTCCCTGCTGTTACCTAA-3'

  • siROC1-2: 5'-CTGTGCCATCTGCAGGAACCACATT-3'

• Delivery Method: Use Lipofectamine RNAiMAX transfection reagent for transient transfection or lentiviral vectors (LT-ROC1) for stable knockdown .

• Controls: Include scrambled siRNA controls such as:

  • siCONT: 5'-ATTGTATGCGATCGCAGACTT-3'

• Validation: Confirm knockdown efficiency via:

  • qRT-PCR with β-actin as internal control

  • Western blot analysis with appropriate loading controls (β-actin, GAPDH)

• Functional Assays:

  • Proliferation: ATPlite assay, cell counting

  • Survival: Clonogenic assay, soft agar colony formation

  • Apoptosis: FACS analysis for sub-G1 population, caspase activation

  • Cell cycle: G2/M arrest analysis

  • Migration/Invasion: Wound-healing assay, Transwell-invasion assay

How can researchers study the role of ROC1 in NF-κB signaling pathway activation?

To investigate ROC1's role in NF-κB signaling activation:

• Protein Expression Analysis: Use Western blot to monitor key pathway components:

  • ROC1

  • IKKα/β and phospho-IKKα/β (Ser176/180)

  • NF-κB/p65 and phospho-NF-κB/p65 (Ser536)

  • IκBα and phospho-IκBα (Ser32)

• Nuclear Translocation: Track p65 nuclear translocation via:

  • Immunofluorescence staining

  • Nuclear/cytoplasmic fractionation followed by Western blot

• Ubiquitination Analysis:

  • Cycloheximide (CHX) chase assay (30 μM) to study p-IκBα degradation kinetics

  • MG132 proteasome inhibitor treatment (20 mM) to confirm proteasome involvement

  • Immunoprecipitation of p-IκBα followed by Western blot with anti-ubiquitin antibody

• Pathway Validation:

  • NF-κB inhibitor (BAY 11-7082, 5 μM) treatment

  • siRNA knockdown of IκBα

• Target Gene Expression:

  • qRT-PCR and Western blot analysis of metastasis-related NF-κB target genes (uPAR, ICAM1, VCAM1, MMP9)

What techniques can be used to evaluate ROC1-mediated effects on cancer cell invasion and metastasis?

To evaluate ROC1's effects on invasion and metastasis:

• In Vitro Assays:

  • Wound-healing assay: Scratch 90% confluent cultures with a 200-μL pipette tip; monitor closure at 0 and 24h

  • Transwell-invasion assay: Use 8-μm pore BioCoat Matrigel Invasion chambers; seed 50,000 cells/well in serum-free medium; stain migrated cells with 0.1% crystal violet

• In Vivo Metastasis Model:

  • Generate luciferase-labeled cancer cells with ROC1 overexpression or knockdown

  • Inject cells (1 × 10^6 in 200 μL PBS) into tail veins of nude mice

  • Monitor metastasis development via in vivo bioluminescence imaging

  • Quantify lung metastatic nodules after sacrifice (8 weeks post-injection)

  • Perform IHC analysis of metastatic tissues for ROC1 and metastasis-related markers

• Molecular Analysis:

  • Epithelial-mesenchymal transition (EMT) marker assessment

  • ROC1-regulated DEPTOR accumulation and mTOR kinase activity inhibition

How does ROC1 contribute to cancer cell senescence and apoptosis pathways?

ROC1 silencing induces multiple cellular responses through distinct mechanisms:

Senescence Induction:

• ROC1 silencing triggers senescence coupled with DNA damage, as evidenced by morphological changes and SA-β-galactosidase staining

• This occurs independently of canonical p53/p21 and p16/pRB pathways

• In bladder cancer, ROC1 downregulation causes DEPTOR accumulation, inhibiting mTOR kinase activity and promoting mesenchymal-epithelial transformation

Apoptosis Activation:

• Approximately 30-40% of ROC1-silenced cells undergo apoptosis versus 5-10% in control cells

• Molecular changes include:

  • Accumulation of pro-apoptotic protein Puma

  • Reduction of anti-apoptotic proteins (Bcl-2, Mcl-1, survivin)

  • Activation of both intrinsic and extrinsic apoptotic pathways

• Caspase activation cascade including:

  • Decrease in pro-caspase forms (caspases 3, 7, 8, and 9)

  • Appearance of cleaved active forms (caspases 3 and 7)

  • PARP cleavage

Cell Cycle Regulation:

• G2/M arrest associated with:

  • Accumulation of 14-3-3σ

  • Elimination of cyclin B1 and Cdc2

What is the mechanistic relationship between ROC1 and NF-κB signaling in promoting cancer metastasis?

ROC1 activates NF-κB signaling through a well-defined mechanistic pathway:

• Ubiquitination Enhancement: ROC1, as part of CRL complexes, specifically enhances the ubiquitination of phosphorylated inhibitor of kappa B alpha (p-IκBα) .

• IκBα Degradation: This ubiquitination targets p-IκBα for proteasomal degradation, removing its inhibitory effect on NF-κB/p65 .

• Nuclear Translocation: With IκBα degraded, p65 translocates to the nucleus as demonstrated by immunofluorescence and nuclear fraction analysis .

• Target Gene Activation: Nuclear p65 promotes transcription of metastasis-related genes:

  • urokinase-type plasminogen activator receptor (uPAR)

  • intracellular adhesion molecule 1 (ICAM1)

  • vascular cell adhesion molecule 1 (VCAM1)

  • matrix metalloproteinase 9 (MMP9)

• Functional Consequences: This transcriptional program ultimately promotes cancer cell invasion and metastasis, as validated in both in vitro and in vivo models .

Linear regression analysis demonstrates a significant Pearson correlation between ROC1 and nuclear p65 expression in bladder cancer tissue microarray samples, further supporting this mechanistic relationship .

What are common technical challenges in ROC1 knockdown experiments and how can they be resolved?

Common challenges and solutions in ROC1 knockdown experiments:

For efficient ROC1 knockdown validation, perform both qRT-PCR and Western blot analysis 48-72 hours post-transfection before proceeding with functional assays .

How can researchers optimize ROC1 antibody-based immunoprecipitation for studying protein interactions?

Optimizing ROC1 antibody immunoprecipitation for protein interaction studies:

• Antibody Selection:

  • Choose antibodies validated for immunoprecipitation applications

  • Consider using tagged ROC1 (ROC1-Flag) systems when direct IP is challenging

• Lysate Preparation:

  • Use appropriate lysis buffers that preserve protein interactions

  • Include protease inhibitors and phosphatase inhibitors when studying phosphorylated interactors

  • Perform cell lysis under non-denaturing conditions

• Pre-clearing:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Immunoprecipitation Protocol:

  • Use Pierce Classic Magnetic IP/Co-IP Kit or similar for consistent results

  • Optimize antibody concentration and incubation conditions

  • Include appropriate negative controls (IgG or irrelevant antibody)

• Washing Conditions:

  • Optimize washing buffer stringency to balance between removing non-specific interactions and preserving genuine interactions

  • Consider performing sequential washes with increasing stringency

• Elution and Analysis:

  • Elute under mild conditions to preserve interacting proteins

  • Analyze by SDS-PAGE followed by Western blotting with specific antibodies

  • For comprehensive interaction studies, consider mass spectrometry analysis

What factors affect ROC1 antibody specificity in immunohistochemistry and how can they be controlled?

Factors affecting ROC1 antibody specificity in IHC and their controls:

• Fixation Parameters:

  • Overfixation can mask epitopes

  • Standardize fixation time (typically 24-48 hours in 10% neutral buffered formalin)

  • Consider testing alternative fixatives for specific applications

• Antigen Retrieval:

  • Optimize heat-induced epitope retrieval (HIER) methods

  • Test different pH conditions and retrieval buffers

  • Standardize retrieval time and temperature

• Antibody Validation:

  • Confirm specificity using positive controls (cancer tissues with known ROC1 overexpression)

  • Include negative controls (normal tissues with low ROC1 expression)

  • Validate antibody specificity using ROC1 knockdown tissues/cells

• Blocking Protocol:

  • Optimize blocking to reduce non-specific binding

  • Address endogenous peroxidase activity

  • Consider tissue-specific blocking reagents

• Signal Development System:

  • Select appropriate detection systems based on expected expression levels

  • Standardize development time to avoid background

  • Use appropriate positive and negative controls on each slide

• Quantification Methods:

  • Use standardized scoring systems

  • Consider digital image analysis using software like ImageJ for consistent quantification

  • Calculate integral optical density (IOD)/unit area for precise comparative analyses